In summary, this study demonstrates that obesity is associated with increased use of bronchodilators and increased diagnosis of asthma in the community. However, the prevalence of significant airflow obstruction is lower in the obese than in the nonobese groups. This suggests that OAD might be overdiagnosed in the obese and overweight population, leading to the overuse of bronchodilators. Population-based prospective studies are needed to confirm these early findings and to better determine the role of obesity on the diagnosis and treatment of patients with asthma in the community.